This inventor holds 1 USPTO granted patent. Top assignees: Sloan-Kettering Institute for Cancer Research, Tri-Institutional Therapeutics Discovery Institute. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 519 
1 out of 11 Years Active: 2025
Title: Carles Monterrubio Martinez: Innovator in Cancer Therapy
Introduction
Carles Monterrubio Martinez is a prominent inventor based in Boston, MA (US). He has made significant contributions to the field of cancer therapy through his innovative research and development of targeted drug delivery systems. His work focuses on improving PI3K inhibitors, which are crucial in the treatment of various proliferative diseases, including cancer.
Latest Patents
Carles Monterrubio Martinez holds a patent for "PI3K inhibitors and uses thereof." This patent represents a significant advancement in cancer therapy by developing a new, targeted drug delivery paradigm. The patent details compounds, such as those of Formula (I) and (II), along with their pharmaceutically acceptable salts, hydrates, solvates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs. These PI3K inhibitors, particularly PI3Kα inhibitors, are designed for the treatment and prevention of various diseases, especially cancer. The patent also discusses nanoparticles and nanogels that encapsulate these compounds for targeted delivery to cancer cells or tumors.
Career Highlights
Throughout his career, Carles has worked with esteemed organizations such as the Sloan Kettering Institute for Cancer Research and the Tri-Institutional Therapeutics Discovery Institute. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Carles has collaborated with notable colleagues, including Makoto Fushimi and Maurizio Scaltriti. These partnerships have further enhanced his research and development efforts in cancer therapy.
Conclusion
Carles Monterrubio Martinez is a dedicated inventor whose work in developing PI3K inhibitors has the potential to transform cancer treatment. His innovative approach and collaborations with leading institutions and experts underscore his commitment to advancing medical science.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile